CN104789514B - A kind of amicine overexpression DNA vaccination and construction method and application - Google Patents
A kind of amicine overexpression DNA vaccination and construction method and application Download PDFInfo
- Publication number
- CN104789514B CN104789514B CN201510175578.5A CN201510175578A CN104789514B CN 104789514 B CN104789514 B CN 104789514B CN 201510175578 A CN201510175578 A CN 201510175578A CN 104789514 B CN104789514 B CN 104789514B
- Authority
- CN
- China
- Prior art keywords
- pegs
- tpa
- mouse
- plasmid
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011238 DNA vaccination Methods 0.000 title abstract description 10
- 230000002018 overexpression Effects 0.000 title abstract description 8
- 238000010276 construction Methods 0.000 title abstract description 4
- 239000013612 plasmid Substances 0.000 claims abstract description 60
- 230000006651 lactation Effects 0.000 claims abstract description 41
- 230000012010 growth Effects 0.000 claims abstract description 24
- 230000001488 breeding effect Effects 0.000 claims abstract description 8
- 238000009395 breeding Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 15
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 7
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 13
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 abstract description 12
- 241000588724 Escherichia coli Species 0.000 abstract description 9
- 108091008146 restriction endonucleases Proteins 0.000 abstract description 9
- 238000005859 coupling reaction Methods 0.000 abstract description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 abstract description 2
- 229930027917 kanamycin Natural products 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 63
- 229960005486 vaccine Drugs 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 39
- 229940088597 hormone Drugs 0.000 description 36
- 239000005556 hormone Substances 0.000 description 36
- 108010051696 Growth Hormone Proteins 0.000 description 33
- 102100038803 Somatotropin Human genes 0.000 description 33
- 239000000122 growth hormone Substances 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 30
- 230000002401 inhibitory effect Effects 0.000 description 29
- 235000013336 milk Nutrition 0.000 description 29
- 239000008267 milk Substances 0.000 description 29
- 210000004080 milk Anatomy 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 24
- 241000700159 Rattus Species 0.000 description 23
- 239000000523 sample Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 238000001890 transfection Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 108010076504 Protein Sorting Signals Proteins 0.000 description 17
- 108010056088 Somatostatin Proteins 0.000 description 17
- 230000003053 immunization Effects 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 241000283690 Bos taurus Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000029087 digestion Effects 0.000 description 14
- 230000036039 immunity Effects 0.000 description 14
- 230000028327 secretion Effects 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 102000005157 Somatostatin Human genes 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 13
- 229960000553 somatostatin Drugs 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 11
- 108010041986 DNA Vaccines Proteins 0.000 description 10
- 229940021995 DNA vaccine Drugs 0.000 description 10
- 238000012449 Kunming mouse Methods 0.000 description 10
- 210000005075 mammary gland Anatomy 0.000 description 10
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 239000013613 expression plasmid Substances 0.000 description 8
- 239000003292 glue Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 101001075372 Mus musculus Gamma-glutamyl hydrolase Proteins 0.000 description 6
- 101000687471 Mus musculus Prolactin Proteins 0.000 description 6
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 6
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 6
- 238000000246 agarose gel electrophoresis Methods 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108010057464 Prolactin Proteins 0.000 description 5
- 102100024819 Prolactin Human genes 0.000 description 5
- 102100022831 Somatoliberin Human genes 0.000 description 5
- 101710142969 Somatoliberin Proteins 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 229940097325 prolactin Drugs 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 4
- 101000878982 Mus musculus Squalene synthase Proteins 0.000 description 4
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000556 factor analysis Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010010 raising Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000003118 sandwich ELISA Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 229960000187 tissue plasminogen activator Drugs 0.000 description 4
- 101800000414 Corticotropin Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 108010006025 bovine growth hormone Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- AKPKWZRKZOAAAZ-UHFFFAOYSA-N 2-[2-(diaminomethylideneamino)ethylsulfanylmethyl]-3-sulfanylpropanoic acid Chemical compound NC(N)=NCCSCC(CS)C(O)=O AKPKWZRKZOAAAZ-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101000885147 Enterococcus avium D-arabitol-phosphate dehydrogenase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- 241000282849 Ruminantia Species 0.000 description 2
- 108010051611 Signal Recognition Particle Proteins 0.000 description 2
- 102000013598 Signal recognition particle Human genes 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000020246 buffalo milk Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000012215 gene cloning Methods 0.000 description 2
- 201000010284 hepatitis E Diseases 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000893 inhibin Substances 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000009940 knitting Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000023247 mammary gland development Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001646 thyrotropic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 101001075376 Bos taurus Gamma-glutamyl hydrolase Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000007232 Eastwood olefination reaction Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010059410 Faecaluria Diseases 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101100466198 Mus musculus Ptpra gene Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 101150050480 SS gene Proteins 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229940097265 cysteamine hydrochloride Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 229940023832 live vector-vaccine Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940062190 pancreas extract Drugs 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000012031 short term test Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 101150010939 tpa gene Proteins 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a kind of amicine overexpression DNA vaccination and construction method and applications, plasmid pEGS/2SS is digested with I two restriction endonucleases of Xho I and EcoR, obtaining the both ends containing kanamycins has the pEGS/2SS segments of I two restriction enzyme sites of Xho I and EcoR, then by synthetic tpa and pEGS/2SS segment coupled reactions, plasmid pEGS/2SS tpa are obtained.Escherichia coli will be obtained in plasmid pEGS/2SS tpa conversion competent escherichia coli cells DH5aEscherichia coliDH5 α (pEGS/2SS tpa), deposit number:CCTCC NO:M2015105.Mouse is immunized using plasmid pEGS/2SS tpa as DNA vaccination, mouse growth, breeding and lactation can be promoted, had broad application prospects.
Description
Technical field
Structure and application the present invention relates to animal DNA vaccine overexpress DNA epidemic diseases more particularly to a kind of amicine
Seedling and construction method and application.
Technical background
Growth hormone release inhibiting hormone (Somatostatin, SS) gene vaccine is exactly by by the gene cloning of encoding growth chalone -14
The recombinant plasmid constructed on carrier for expression of eukaryon.Then the plasmid is imported in animal body, makes SS-14 in vivo
Active polypeptide is given expression to, the antibody of anti-growth hormone release inhibiting hormone is generated by immune response to reach the mesh for neutralizing endogenous growth chalone
, so as to promote growth of animal and lactation.Obviously, play main function in this approach is growth hormone release inhibiting hormone.According to growth
The effect of chalone " inhibiting somatotropin (growth hormone, GH) and the release of lactagogue parahormone ", recent year close
Just have in terms of growth of animal and lactation is promoted in the studies have shown that SS genetic immunizations in terms of animal reproduction in SS genetic immunizations
Effect, and obtain more apparent immune effect.
It is well known that dairy products are as a kind of high-quality liquid food full of nutrition, comprehensive, digestibility is high, it is more next
More liked by consumers in general, and by common concern.Contain abundant protein, carbohydrate, amino acid, dimension life in fresh milk
Element, minerals and enzyme etc., and the sequence of milk nutritional ingredient is according to this from high to low buffalo milk, goat milk, Holstein cow milk, people's milk and
Mare's milk.This is because compared with ordinary milk, the comprehensive nutrient value of buffalo milk is higher by nearly 2 times, and casein content is high, and courage is solid
Alcohol is low, and somatic number is low, and dry matter content (17.5%) is 0.5 times high, and unsaturated fatty acid content is 60-100 times high, and protein contains
Amount (4%) is 0.5 times high, and butterfat percnetage 7.5%, calcium content is 0.3 times high, and Zn content is 12 times high, and iron content is 78 times high, and vitamin A contains
It measures high 32 times (Zhang Chunxi 2006).Therefore, often drinking-water milk can promote more tyrosine calcium uptakes, contribute to bone and intelligence
Development reduces cardiovascular disease incidence rate, improves the immunity of the human body.However the 6.4% of the milk total output Jin Zhan worlds of China, breast
The product level of consumption is the 1/5 of world average level, while buffalo lactation amount, reproductive efficiency genetic force are relatively low.Above-mentioned present situation
Presence cause must to improve milk-quality and milk performance expansion research.
It is to have the example governed that growth hormone release inhibiting hormone, which is applied to animal lactation,.The chemical antagonist cysteamine of the SS such as Wang Yanling
(cysteamine hydrochloride, CSH) feeds the holstein cow of lactation mid-term, finds daily yielding and the feeding of milk cow
Material conversion ratio all significantly improves (Wang Yanling etc. 1999).According to reports such as Sun, external source SS hormone active immunity lactation ewes are used
Its lactation amount (Sun et al.1990) can be significantly improved.Imgap has found when in immune rat, only active immunity SS-14
The antibody of anti-SS could be generated and improve the output of milk (Yi et al.1999).Xiao Shenhua " swashing No. 1 raw " (i.e. a kind of SS weights
Group vaccinia virus live vector vaccine) milk cow is immunized, play the role of promoting lactation, and make under the output of milk of Lactation of Dairy Cow middle and later periods
Drop process slows down, but milk-quality is uninfluenced (Xiao Shen China 2005).More than result of study shows using somatostatin DNA vaccine
Milk performance to improve domestic animal is feasible.
Tissue plasminogen activator (tissue plasminogen activator, tpa) is a special positioning
In the signal peptide of endoplasmic reticulum, the albumen that can be coupled is directly transferred into endoplasmic reticulum, and antigen is avoided to be processed and is transported to cytoplasm, mesh
Albumen with secreted form, a large amount expression can ensure the maintenance of ideal immunogenicity in vivo.Tpa molecules include 4 structures
Domain, one is 47 residues in F areas, i.e. N-terminal, same with adjusting the finger structure domain of fibrin plates of fibronectin
Source;The second is E areas, homologous with epidermal growth factor;The third is two loop domains of K1 and K2;The fourth is P areas, i.e. serine
Protease area (Pennica et al.1983).Wherein, the function in F areas and K2 areas is combined with fibrin, passes through F areas, E areas
It is quickly removed under the adjusting of polysaccharide chain, and P areas then play enzymatic activity (Lijnen and Collen 1991).With extraction and
The accuracy of purification process improves, and researcher has found that tpa is mainly discharged, and tpa swashs with blood vessel plasminogen by endothelial cell
Being (vascular plasminogen activator, vpa), blood activator of plasminogen (blood plasminogen
Activator, bpa) there is immune homology, but be different from plasma urokinase-type plasminogen activator (urokinase
plasminogen activator,upa)(Rijken et al.1980).Show that tpa is by further Biochemical Research
Main component in fibrinolytic system, physiological regulation fibrinolysis;
However, tpa is not only the major function factor in fibrinolytic system, it is one that structure, which also determines it,
Efficient signal peptide.Therefore, tpa has the shared effect of all signal peptides, i.e., first by signal recognition particle (signal
Recognition particle, SRP) identification, it is attached on ER films and carries out signal identification, by the ribosomes in translation state
It is incorporated on RER films, after ribosomes completes translation, the maturation protein of clipped modification will be secreted along peptide approach cross-film is led
To extracellular.In addition, as signal peptide, tpa can not only make its coupling protein become secretory protein, but also convenient for fixed in cell
Position protein and new polypeptide chain (Wei Xuefang etc. 2006).At present, the tpa signal peptides of 23bp have been used as heterologous leader sequence, by with
Destination protein is brought into method (Yang et al.2001, Costa et al.2006, the Jalah et of cell secretory pathway by work
al.2007,Golden et al.2008,Luo et al.2008,Kaur et al.2009,Seo et al.2009).With
Afterwards, the application of tpa is not limited solely to the research of cellular level, but is constantly generalized to other field, is especially prevented for structure
New approach is opened in terms of the gene vaccine of Animal diseases.Because modificator gene vaccine generates efficiently and a large amount of immune anti-
Should, depending on expressing the secretion capacity (Wa tanabe et al.2003, Liang et al.2005) of antigen;And in gene epidemic disease
The presence of Miao Zhong, tpa signal peptide can effectively improve secretion of the recombinant protein to extracellular medium, and body is induced to generate pathogen
Very strong immune response (Li et al.1999, Alves et al.2000, Ashok and Rangarajan 2002).
Sinone M.Costa etc. merge tpa with the NS1 full-length genes of dengue fever virus DENV-2, the vaccine of structure
The NS1 albumen of recombination is secreted into surrounding medium by pcTPANS1 with dimeric forms, and higher is generated compared with the control group after attacking poison
Horizontal NS-1 specific antibodies, and based on IgG1, it is intended to Th2 types reaction (Costa et al.2006, Costa et
Al.2007, Yao Yan are rich 2012).Yang etc. is the antibody activity for improving Hepatitis E vaccine, is compared in Hepatitis E virus
HVE-p179 N-terminals merge tpa signal peptides and are inserted into 3 C3d complements repetitive sequence both sides in HVE-p179 C-terminals
Formula, finds in the antibody generated after being immunized and the level of antigen is improved, and the Hepatitis E vaccine for merging tpa generates antibody
Time is done sth. in advance 2 weeks (Yang et al.2010).It is continued to use however, the application about tpa signal peptides does not terminate in simple duplication.
Wang has found that tpa signal peptides 22 sport the third ammonia by proline when trimer protein structural domain is introduced into plasmid vector
Acid or glycine can improve the expression of destination protein and secretion situation (Wang et al.2011).In addition to this, correlative study
It emerges in an endless stream, such as the Flu-A vaccine ptPAs/NP of the segment containing tpa, pulmonary tuberculosis DNA vaccination, the people that conjunction with electroporation is immunized
Papillomavirus (papillomavirus, HPV) vaccine etc. (Delogu et al.2002, Luo et al.2008, Seo
et al.2009).In short, after the target gene in carrier is coupled with tpa signal peptides, destination gene expression is not only made to secrete shape
Formula albumen, and humoral immunity level (Wang et al.2004, Costa et al.2006) can be enhanced.
Lactation is one and breaks up from breast tissue to the physiology course to play a role, relates generally to mammogenesis, lactation hair
The dynamic and links such as maintenance and mammary gland, and each stage is to participate in by hormone.Mammary gland development is
Since fetal period, body of gland and conduit system at this time is still undeveloped, with jenny ontogeny, estrogen and pregnant
Hormonal readiness improves, and estrogen promotes the growth of breast duct, and progestational hormone stimulates development (the Lamote et of mammary gland alveolus
al.2004).And the synthesis of IGFs in estrogen stimulation breast stroma cell, so as to which galactophore epithelial cell be promoted to generate
(Tucker 2000).In addition, galactagogin (Prolactin, PRL), corticotropin
(adrenocorticotrophic hormone, ACTH), thyrotropic hormone (thyrotropic hormone, TSH) etc. swash
Element and environmental stimuli can influence breast cell proliferation.Lactation is started during childbirth, is noteworthy characterized by prolactin and sugar at this time
The secretion of cortin peaks.Based on peak of lactation decomposed with alienation, the raising of GH levels and insulin and thyroid gland swash
Cellulose content reduces;Hereafter based on assimilation synthesis (Zhang Shaoying 1990).But the startup of lactation and maintenance stage mainly by PRL and
The regulation and control of GH.For ruminant, GH and PRL joint effect lactation amounts, GH influences butterfat synthesis, and PRL influences lactoprotein
With the synthesis (Knight 2001) of lactose.Cortisol can maintain the secretion activity of epithelial cell, but not find that it promotes milk life
Into effect (Sjaastad et al.2010).
It is found by researches that not only containing SS in blood plasma, the presence of SS is also can detect in milk.Only 70% in blood plasma
SS is SS-28, and only has SS-14 in milk.This is because PC-1 protease-baseds are only expressed in the breast tissue of mammal
Cause, PC-1 protease can promote growth promotion chalone original to synthesize SS-14 (Werner et al.1985, Holst et al.1990).
The research of Chen et al. points out that a kind of detectable unique neuropeptide is exactly SS, and infer that SS can in the mammary gland of rat
It can participate in lactation activity, i.e., the development of mammary gland and function (Chen et al.1999).In addition, SS can be in the association of estrogen
Inhibit the secretion (Lee and Shin 1996) of PRL under same-action.
For ruminant, PRL is the required factor for starting lactation.However, lactation, once being started, PRL is just
No longer it has been the limiting factor (Zhang Shaoying 1990) for determining lactation amount height.Early in 1940, British scientist just confirmed that GH can
There can be certain lactagogue effect (Peel and Bauman 1987).At present, with hypophysis or genetic recombination bovine growth hormone
(bST) practice result for improving lactation amount more demonstrates the effect that GH maintains lactation.Han Zheng's health etc. is daily to every cow in milk
12.5-50mg GH are injected, as a result, it has been found that the milk production of cow in milk can generally improve 15-24% after injection, and its feed conversion
Efficiency can increase 5-20% (Han Zheng's health 1999).In fact, GH and it is indirect mammary gland is had an impact, but GH first stimulates liver,
Liver is made to generate IGFs, and IGFs can influence mammary gland activity (seedling tree monarch 1999).That is, GH by IGFs between medium
It connects stimulation mammary glandular cell to break up, enhances the milking capacity of mammary gland.GH, which has, to be coordinated to organize the competition to nutrition outside mammary gland and mammary gland,
Reduce the nutriment intake organized outside mammary gland.Research in terms of Neuroendocrinology it has been experienced that GH by hypothalamus
It is dual with the growth hormone releasing hormone (growth hormone releasing hormone, GHRH) and SS of gastrointestinal tract release
Regulation and control, the i.e. secretory volume of GH are balanced by the collective effect of both hormones of GHRH and SS.Therefore, some researchs are by regulating and controlling to promote
It is secreted into GHRH or SS levels is inhibited to improve the content of internal GH, so as to achieve the effect that improve lactation amount (Han Zheng's health
1999).Much research shows that, lactation amount can be improved 20-30% using the method for GH injection cows in milk, through examining the method
It can't influence composition of milk or the health status (seedling tree monarch 1999) of ox.The researchers such as Machlin, Baird pass through respectively
It injects in the GH to lactating cow body that the GH extracted and DNA are re-combined into, the milk performance of lactating cow is made all to improve 10-
25% (Machlin 1973, Baird and Durkin 1986).Cornell Univ USA in 1981 uses recombination methionyl ox
Growth hormone (MBS) carries out a short term tests to milk cow, the results showed that is increasing lactation amount in terms of this, MBS spreads out with hypophysis
The effect of raw GH is quite (Peel and Bauman 1987).The bovine growth hormone that Chadio etc. is produced with genetic recombination
(bovine growth hormone, bST) handle lactation period goat, find in addition to lactation amount is improved, also improve butterfat with
The content of lactose, but the changes of contents of lactoprotein is less (Chadio et al.2000).In addition, Castigliego etc. is to being in
The milk cow effect bST of lactation period, detects that bST the and IGF-1 levels in processing milk cow blood plasma significantly rise
(Castigliego et al.2009).Nowadays recombinant bovine GH is applied in dairy industry production by the U.S., and the country also has
Similar research obtains preferable achievement.Such as the culture Escherichia coli such as land east woods, obtain the thick of bST using gene recombination technology
Extract handles milk cow one month with this, and every bovine lactation amount increases 1.65kg/d (about 10.75%), but butterfat percnetage, newborn density
Etc. indexs have no difference (Lu Donglin etc. 1990).Although test method is different with Testing index, must for GH can promote
The Milking ability of mammal.
From the point of view of document above report, tpa signal peptides and growth hormone release inhibiting hormone SS gene vaccines cooperate with animal lactation and
Breeding effect is at home and abroad without relevant report, therefore the present invention weighs original somatostatin DNA vaccine pEGS/2SS
Group constructs the novel overexpression somatostatin DNA vaccine of the peptide fragment of signal containing tpa, it is intended that improve the vaccine to animal immune
Originality, lactation and the effect of breeding, and use condition and immune programme optimal case are inquired into, it is New somatostatin gene vaccine
Application in the actual production process provides theoretical foundation.
Invention content
The defects of it is an object of the invention to overcome existing somatostatin gene immunological technique, provides a kind of overexpression life
The eukaryon expression plasmid pEGS/2SS-tpa of long chalone, the plasmid are that tpa segments are inserted into plasmid pEGS/2SS with I Hes of Xho
EcoR I is obtained.
It is another object of the present invention to provide a kind of bacterial strains for including plasmid pEGS/2SS-tpa;The bacterial strain is
It is sent on March 12nd, 2015 to China typical culture collection center preservation, Classification And Nomenclature:Escherichia coli Escherichia
Coli DH5 α (pEGS/2SS-tpa), deposit number:CCTCC NO:M2015105, the bacterial strain are extracted by SDS alkaline lysis
It can obtain pEGS/2SS-tpa plasmids.
Final object of the present invention is to provide a kind of eukaryon expression plasmid pEGS/2SS- for overexpressing growth hormone release inhibiting hormone
Tpa or comprising the application in amicine DNA vaccination is prepared its Escherichia coli, is applied to mouse by the DNA vaccination, shows
Work improves mouse growth, breeding and the function of lactation.
The present invention is implemented by following technical solution:
A kind of eukaryon expression plasmid pEGS/2SS-tpa for overexpressing growth hormone release inhibiting hormone, is prepared by the following method to obtain
Plasmid pEGS/2SS with I two restriction endonucleases of Xho I and EcoR is digested first, is obtained containing kanamycins
There are the pEGS/2SS segments of I two restriction enzyme sites of Xho I and EcoR at both ends, and synthetic tpa segments then are passed through Xho
I and EcoR, I two endonuclease digestions obtain the tpa segments of I two restriction enzyme sites of Xho I and EcoR, by the gene piece
Section and pEGS/2SS segment coupled reactions, obtain plasmid pEGS/2SS-tpa.
By in plasmid pEGS/2SS-tpa conversion competent escherichia coli cells DH5a, obtain using Escherichia coli as carrier
Ultra high efficiency starts expression somatostatin DNA vaccine.The bacterial strain is sent on March 12nd, 2015 into China typical culture collection
Heart preservation, Classification And Nomenclature:Escherichia coli Escherichia coli DH5 α (pEGS/2SS-tpa), deposit number:CCTCC
NO:M2015105, preservation address:Wuhan, China Wuhan University;The bacterial strain can obtain pEGS/ by the extracting of SDS alkaline lysis
2SS-tpa plasmids.
Escherichia coli Escherichia coli DH5 α (pEGS/2SS-tpa) is contain tissue plasminogen activator
(tpa) mixed culture of growth hormone release inhibiting hormone eukaryon expression plasmid pEGS/2SS-tpa can be obtained by the extracting of SDS alkaline lysis
To pEGS/2SS-tpa plasmids.Culture medium:1L LB solid mediums form:10g sodium chloride, 5g yeast extracts, 10g pancreas eggs
White peptone, 1.5g agar powders.Condition of culture:pH:6.8-7.8, temperature:37 DEG C, be Kan+Resistance;With flat in LB solid mediums
Plate method of scoring detects whether the culture survives.
A kind of eukaryon expression plasmid pEGS/2SS-tpa for overexpressing growth hormone release inhibiting hormone is in amicine DNA vaccination is prepared
Application, after being mixed using the plasmid as vaccine direct immunization animal or with DNA vaccination adjuvant be immunized animal.
It has been applied successfully to improve growth of animal, breeding and milk performance in the present invention, such as improved in mouse
The application of the function of growth, breeding and lactation.
More detailed technical solution is shown in《Specific embodiment》.
Compared with prior art, the present invention has the following advantages:
1st, a kind of efficient eukaryon expression plasmid pEGS/2SS-tpa for starting amicine has been obtained;
2nd, obtained it is a kind of can in the growth, breeding and milk performance of mouse remarkable result growth hormone release inhibiting hormone DNA epidemic diseases
Seedling pEGS/2SS-tpa.There is certain superiority to judge by the Cluth size index of female rat on reproductive performance, pEGS/2SS-
Tpa vaccine experiments group is more 1 higher than pEGS/2SS growth hormone release inhibiting hormone positive controls, than feminine gender group pEGFP-N1 up to 1.4 ≈ 2
Only;By the Body Mass Index for newborn mouse of weaning, pEGS/2SS-tpa groups can be obtained than pEGS/2SS growth hormone release inhibiting hormone positive controls
Weight is high by 10.7%, higher than negative control group pEGFP-N1 by 21.8%;And efficiently start vaccine high dose group (200 μ g/ only),
Add and exempt from weightening, the reproductive performance best results of 1 time.
Description of the drawings
Fig. 1 builds collection of illustrative plates for eukaryon expression plasmid pEGS/2SS-tpa.
Fig. 2 is the electroresis appraisal figure for synthesizing segment tpa.
M is 50bp DNA Ladder Marker;1-3 swimming lanes are the signal peptide tpa after annealing to be measured through 1% agarose
The result of detected through gel electrophoresis.
Fig. 3 identifies collection of illustrative plates for eucaryon plasmid carrier pEGS/2SS digestions.
M represents DL 2,000Marker;1 swimming lane is eucaryon plasmid carrier pEGS/2SS through I Hes of restriction enzyme EcoR
Result after I double digestions of Xho.
Fig. 4 identifies collection of illustrative plates for eucaryon plasmid carrier pEGS/2SS-tpa digestions.
M representation DNAs ladder;1 swimming lane is plasmid pEGS/2SS-tpa electrophoresis results, and 2 swimming lanes are plasmid pEGS/2SS-
Results of the tpa after I double digestion of restriction enzyme Xho I and EcoR.
Fig. 5 is expression and the distribution situation that different plasmids Plasmids transfect MCF-7 cell GFP green fluorescences.
In wherein Fig. 5 A for tri- kinds of plasmid transfection MCF7 cells of pEGFP-N1, pEGS/2SS and pEGS/2SS-tpa for 24 hours after
Observe the expression of GFP green fluorescences.Bright and fluorescence be respectively in the observation off field of light field and fluorescence as a result,
Scale represents 200 μm.
B is observes in Fig. 5 after tri- kinds of plasmid transfection MCF7 cells 48h of pEGFP-N1, pEGS/2SS and pEGS/2SS-tpa
The expression of GFP green fluorescences.Bright and fluoresce is the observation result in light field and fluorescence off field respectively;Scale generation
200 μm of table.
C is observed afterwards for 24 hours for tri- kinds of plasmid transfection MCF7 cells of pEGFP-N1, pEGS/2SS and pEGS/2SS-tpa in Fig. 5
The distribution situation of GFP green fluorescences;Scale represents 200 μm.
Fig. 6 is the overexpression effect comparison chart that quantitative real-time PCR eucaryon plasmid transfects SS after MCF-7 cells.
PEGFP-N1, pEGS/2SS or pEGS/2SS-tpa transfect 48h after MCF-7 cells respectively, detect and are grown in cell
The expression of chalone SS.The expression quantity of SS is standardized with the expression quantity of GAPDH, and expression multiple is existed relative to SS
The expression of pEGFP-N1 transfection groups is finally represented, each data have 3 biological samples to attach most importance to come what is calculated with mean value standard error
It is multiple.**P<0.01
Fig. 7 is protein expression result after eucaryon plasmid pEGS/2SS-tpa transfection MCF-7 cells.
Western Blot detection lifes are utilized after MCF-7 cell transfectings pEGFP-N1, pEGS/2SS and pEGS/2SS-tpa
The expression of long chalone SS-14 albumen;The expression quantity for choosing GAPDH albumen simultaneously is standardized correction, and expression multiple is
It is calculated relative to pEGFP-N1.
Fig. 8 is the agarose gel electrophoresis testing result that Trizol methods extract kunming mice tissue RNA, RNA concentration.
M is DNA ladder, swimming lane 1-10 be successively the heart of kunming mice, liver, spleen, lung, kidney, muscle, small intestine, stomach,
Brain and pancreas tissue RNA.
Fig. 9 is growth hormone release inhibiting hormone SS expression quantity testing results in kunming mice respectively tissue.
Swimming lane 1-9 is the tissue RNA amplification growth hormone release inhibiting hormone of heart, liver, spleen, lung, kidney, muscle, small intestine, stomach, brain successively
As a result.
SS distribution situations in the kunming mice body of 5d after A is immune pEGS/2SS-tpa in Fig. 9;
SS distribution situations in the Mice Body of 5d after B is immune pEGS/2SS in Fig. 9.
Figure 10 is the secretion level result of growth hormone GH after vaccine immunity kunming mice.
Compared with unloaded injection group pEGFPN1, the secretory volume of mouse GH is equal after immune pEGS/2SS and pEGS/2SS-tpa
It is promoted, but mouse GH raisings are not notable after intramuscular injection pEGS/2SS, and inject mouse GH after pEGS/2SS-tpa
Content is significantly higher than the mouse (P of injection pEGS/2SS<0.05).Illustrate that somatostatin DNA vaccine pEGS/2SS can be with after being immunized
Increase the release of GH, this effect is more obvious after being inserted into tpa signal peptides.
Figure 11 is the secretion level result of prolactin PRL after vaccine immunity kunming mice.
Compared with unloaded immune group, the mouse PRL contents of pEGS/2SS and pEGS/2SS-tpa immune groups are improved;And
And mouse PRL contents significantly raising (P compared with injecting the mouse of pEGS/2SS after intramuscular injection pEGS/2SS-tpa<0.05),
The difference extremely significantly (P compared with control group mice<0.01).Illustrate that mouse PRL can be increased after being immunized by somatostatin gene
Secretion, and this facilitation is especially apparent after tpa signal peptides are inserted into.
Figure 12 is the secretion level result of growth hormone release inhibiting hormone SS after vaccine immunity kunming mice.
Compared with unloaded injection group, the secretory volume of mouse SS is declined after immune pEGS/2SS, but is declined not notable;Exempt from
Mouse SS contents are higher than the mouse of control group instead after epidemic disease pEGS/2SS-tpa, although difference is not also notable.Illustrate growth hormone release inhibiting hormone
After gene vaccine pEGS/2SS and pEGS/2SS-tpa are immunized, the SS in mouse blood will not be significantly affected.
Specific embodiment
Embodiment 1:
The structure of eukaryon expression plasmid pEGS/2SS-tpa
1st, tissue plasminogen activator's (tpa) gene cloning and sequence analysis
According in GenBank (ID:5327)plasminogen activator,tissue[Homo sapiens
(human)] gene order, the digestion at its both ends of cDNA sequence of synthesis plasminogen activator, tissue (tpa)
Site is Xho I and EcoR I, and using Primer5.0 primer-design softwares, tpa sequence designs are as follows:(it is tpa sequences in box
Row, both ends are restriction enzyme site)
tpa-F:
5-TCGAG G-3
tpa-R:
3-C CTTAA-3, Sangon Biotech (Shanghai) Co., Ltd. synthesize h by base and obtain tpa gene pieces
Section.
After sequent synthesis, upstream and downstream segment is diluted to every OD and adds 140 μ L ddH2O is made into 10 μM of storage liquid, then will
Two single-stranded annealing form double-strand.Annealing system is mixed with 10 μ L tpa-R for 10 μ L tpa-F, annealing conditions be 95 DEG C of 30s,
72℃2min、37℃2min、25℃2min.Agarose gel electrophoresis detects after annealing, observes electrophoretic band and purpose band is big
It is small to be consistent, it is stored for future use in 4 DEG C.(Fig. 2)
2nd, the digestion and recycling of carrier pEGS/2SS
With restriction enzyme Xho I and I double digestion pEGS/2SS plasmids of EcoR, (Cao Shaoxian, Yang Liguo, Zhang Wenwei wait
The structure of somatostatin DNA vaccine plasmid pEGS/2SS and expression [J] China animal doctor's journal, 2005,25 (5):499-
502.) 16bp, is cut off, exposes the cohesive end at both ends, digestion system is as follows:
Plasmid band is isolated through 1% agarose recycling gel electrophoresis after digestion, uses Ago-Gel DNA QIAquick Gel Extraction Kits
Plasmid large fragment recycling, recycling rear electrophoresis detection are carried out, observation electrophoretic band is consistent with purpose band size.(attached drawing 3)
3rd, target gene connects
The concentration of the pEGS/2SS plasmid enzyme restrictions segment of recycling and the tpa segments of 10 times of dilution is measured respectively, calculates load
The connection volume ratio of body and target fragment is 6:1, pEGS/2SS is connected according to Invitrogen T4DNA Ligase specifications and is carried
Body and target gene tpa segments, 16 DEG C overnight, and linked system is as follows:
4th, recombinant plasmid transformed competence colibacillus bacterium
1) competent bacteria DH5 α (TIANGEN Biotech's production)
2) competent escherichia coli cell DH5 α are taken out ice bath to thaw from -80 DEG C, 10 μ L connection products is added to enter 50 μ L
Mixing in competent cell, and set and do not add the competent cell of connection product as blank control, ice bath 30min;Go to 42
DEG C heat shock 90s, then rapid ice bath 5min;400 μ L LB fluid nutrient mediums are added in, shaking table is adjusted to 200r/min, 37 DEG C of oscillation trainings
Support 1h;100 μ L are gently drawn after mixing, are uniformly applied to using spreader on the LB solid plates containing Kan, after 37 DEG C of culture 12h,
See whether that conversion bacterium colony is grown.
5th, the screening and identification of pEGS/2SS-tpa plasmids
Picking single bacterium colony vibrates expansion culture 8h in the LB fluid nutrient mediums containing Kan, and it is small to carry out plasmid using kit
It carries, tpa (75bp) should be cut out through Xho I and I digestions of EcoR.Digestion system is as follows:
5 μ L digestion products is taken to carry out 1% agarose gel electrophoresis detection, observe electrophoretic band and purpose band size phase
Symbol is sent to Sangon Biotech's sequencing, analyzes sequencing result, plasmid pEGS/2SS-tpa sequencing results
100% compares successfully.It identifies that correct -20 DEG C of pEGS/2SS-tpa plasmids save backup, plasmid pEGS/2SS-tpa is converted
In competent escherichia coli cell DH5a, obtain the ultra high efficiency using Escherichia coli as carrier and start expression somatostatin DNA vaccine.
The bacterial strain is sent on March 12nd, 2015 to China typical culture collection center preservation, Classification And Nomenclature:Escherichia coli
Escherichia coli DH5 α (pEGS/2SS-tpa), deposit number:CCTCC NO:M2015105, the bacterial strain pass through SDS
Alkaline lysis extracting can obtain pEGS/2SS-tpa plasmids.The bacterium solution conservation of the plasmid containing pEGS/2SS-tpa, -80 DEG C of preservations.
(Fig. 4)
Embodiment 2:
The detection of growth hormone release inhibiting hormone overexpression plasmid pEGS/2SS-tpa plasmids protein expression in vitro
1st, inhibin recombinant plasmid pEGS/2SS-tpa transfectional cells
With plasmid extraction kit (being purchased from TIANGEN Biotech (Beijing) Co., Ltd.) extracting Escherichia coli
Escherichia coli DH5 α (pEGS/2SS-tpa) plasmid, treat MCF-7 cells (human breast cancer cell) individual layer grow to
Lipofectamine is pressed during 60%-70%TM2000 lipofectamine boxes (being purchased from Invitrogen companies) specification carries out
Operation, adds 0.2 μ g plasmids and 1.5 μ L Lipofectamine according to every holeTM2000 calculate, and use serum free medium respectively
OPTI-MEM dissolves mixing, is stored at room temperature 5min.Then the plasmid being configured and liposome solutions are mixed in equal volume, room temperature is quiet
Put 20min.Period absorb tissue culture plate in culture medium, PBS clean 2-3 times, add OPTI-MEM culture based on 37 DEG C, 5%
CO2Incubation is handled in incubator.24 orifice plates are taken out after 20min, absorb OPTI-MEM culture mediums, add 100 μ L OPTI-MEM per hole
Culture medium, and 100 μ L plasmid-liposome complex are slowly added dropwise.Cell processing, which is set, is respectively:PEGFP-N1 transfection groups,
PEGS/2SS transfection groups, pEGS/2SS-tpa transfection groups and blank control group, every group sets 3 parallel repetitions respectively.37℃、
5%CO2After cultivating 5-6h in incubator, change DMEM complete culture solutions (i.e. DMEM+15%FBS) into and continue to cultivate.
2nd, inhibin recombinant plasmid pEGS/2SS-tpa transfectional cell egfp expressions
Transfection for 24 hours with after 48h respectively in the cell growth state and green of fluorescence microscopy Microscopic observation different disposal group
Fluorescence judges the transfection efficiency of MCF-7 cells by comparing the white field of cell and green fluorescence intensity, indirectly determining carrier purpose egg
White optimum expression time.
Transfect pEGFP-N1, pEGS/2SS and pEGS/2SS-tpa respectively when MCF-7 cells 80% converge, transfection is for 24 hours
After 48h, under fluorescence inverted microscope, the green fluorescence after blue light excitation in field of view.It can be seen that test group have it is green
Color fluorescence is presented, and transfects the signal strength that the green florescent signal intensity after 48h is apparently higher than after transfection for 24 hours.Therefore, below
Test cell line is using the cell (Fig. 5) of 48h after transfection.
The green fluorescence of pEGFP-N1 and pEGS/2SS transfection group cells is distributed in MCF-7 cells in uniformly continuous,
The green fluorescence of pEGS/2SS-tpa transfection group cells is distributed in cell in scatterplot shape.Illustrate that being inserted into signal peptide tpa segments changes
Expression and distribution of the destination protein in cell makes destination protein be transferred in endoplasmic reticulum and then is secreted into extracellular.(figure
5C)
3rd, the detection of growth hormone release inhibiting hormone plasmid pEGS/2SS-tpa vivoexpressions is overexpressed
The expression of 3.1Western Blot testing goal albumen
The extraction of cell protein:Take cell pyrolysis liquid RIPA, after thawing overturn mixing for several times (if having precipitation can put 37 DEG C it is molten
Solution), packing with protein inhibitor phenylmethylsulfonyl fluoride (PMSF, 100mM) mixing in proportion, makes final concentration of 1mM, now with existing
With.MCF-7 cells after transfection abandon culture solution, and the PBS of 4 DEG C of precoolings is cleaned 2-3 times.Add appropriate lysate, piping and druming cell is abundant
Cracking.10,000rpm centrifugation 3-5min, take supernatant, dispense, -80 DEG C save backup.All of above operation operates on ice.
The measure of protein concentration:Standard curve and sample protein concentration are determined according to BCA determination of protein concentration kits.Tool
Body step is as follows:(1) 0.8mL protein standards is taken to prepare liquid to be added in protein standard (20mg BSA), fully dissolves, is made into
The protein standard liquid of 25mg/mL, uses immediately after preparation;
(2) the protein standard liquid of appropriate 25mg/mL is taken, is diluted to final concentration 0.5mg/mL;
(3) according to sample number, add 1 times of volume BCA reagent B (i.e. A by 50 times of volume BCA reagent As:B=50:1) with appropriate
BCA working solutions, abundant mixing;
(4) standard items are added to by 0,1,2,4,8,12,16,20 μ L in 96 hole elisa Plates, with standard dilutions (i.e.
PBS 20 μ L) are complemented to, i.e. concentration is respectively 0,0.025,0.05,0.1,0.2,0.3,0.4,0.5mg/mL, as gauge orifice;
(5) plus in isometric sample to the sample well of 96 hole elisa Plates, 20 μ L are diluted to;
(6) each hole adds 200 μ L BCA working solutions, 37 DEG C of warm bath 30min;Microplate reader measures 562nm (between 540-595nm
) light absorption value under wavelength;
(7) standard curve is made, sample protein concentration is calculated according to standard curve.
SDS-PAGE electrophoresis:According to the molecular size range 55KDa of destination protein, 15% separation gel, 5% concentration is configured
Glue carries out PAGE gel electrophoresis.It is preventing from cementing leakage during preparative separation glue, a small amount of low concentration agarose gel back cover can be used, then note
Enter separation gel to blank, then divided equally with hydraulic pressure from glue liquid surface, solidify about 30min;Concentration glue is filled it up with after comb is inserted into, and is solidified
1-2h.Plastic plate is put into electrophoresis tank, adds 1 × Tris-Gly of electrophoretic buffer about 400mL.Albumen and Loading before loading
Boiling water bath 5min after Buffer mixing, makes albuminous degeneration.50 μ g of albumen applied sample amount per hole, ice bath electrophoresis, first with constant pressure 80V electricity
About 20min swim to glue and separation gel interface is concentrated, then change constant pressure 120V into and continue electrophoresis about 50min, sample is made to go to glue bottom,
Stop electrophoresis, take out glass plate.
Transferring film:Measure the length and width for taking glue with a yardstick, clip filter paper 6 of corresponding size is opened, is immersed in transferring film buffer solution.According to
Marker bands weigh the approximate location of purpose fusion protein S/2SS-GFP (55KDa) and internal reference Protein G APDH (37KDa), cut
Pvdf membrane of corresponding size is taken, impregnates 3-5min bubble removings in methyl alcohol.Distill water-soaked graphite cake, keep flat opening, by down toward
On placed negative plate, 3 layers of filter paper, pvdf membrane, 3 layers of filter paper and positive plate successively, often spread one layer and catch up with bubble with test tube, cover tightly electrode
Plate.Ice bath electricity turns, 250mA electric currents transferring film about 45min.After transferring film, glue is taken to be put into dyestuff and is dyed, check whether that transferring film is complete
Entirely.
Closing:It is closed using TBST with 1%BSA, room temperature horizontal shaker 1h.
Primary antibody is incubated:TBST washes film 3 times, each 10min;With 0.1%BSA dilution Somatostatin primary antibodies (1:300 is dilute
Release, Santa Cruz) and internal reference GAPDH antibody (1:1000 dilutions, Boster), sealer, 4 DEG C of overnight incubations.
Secondary antibody is incubated:TBST washes film 3 times, each 10min;With 0.1%BSA dilution goat anti-rabbit iggs-HRP (1:1000 is dilute
Release, Boster) incubation at room temperature 1h.
Colour developing:TBST washes film 3 times, each 10min;Developing solution colour developing 3-5min is eventually adding, develops and scans, during exposure
Between 600s;Optical density is calculated with AlphaEaseFC softwares, by the comparison with internal reference Protein G APDH, extrapolates the opposite of albumen
Expression quantity.
Cell protein is carried after different plasmid transfection MCF-7 cells 48h, Western Blot detection growth hormone release inhibiting hormones SS-14's
Relative expression's situation, as a result display is compared with blank control (monk), pEGS/2SS transfection groups and pEGS/2SS-tpa transfection groups
There is band at 55KDa, and in the same size with destination protein;Speculate according to color, MCF-7 cell transfectings pEGS/
The expression quantity of SS is slightly above the expression quantity of SS after transfection pEGS/2SS plasmids after 2SS-tpa plasmids.(Fig. 6)
Embodiment 3:
Influence of the growth hormone release inhibiting hormone overexpression DNA vaccination of the present invention on Kunming mouse to growth and immune response
1st, prepared by vaccine:
Identified correct pEGFP-N1, pEGS/2SS and pEGS/2SS-tpa bacterium solution is added in LBs of the 250mL containing Kan
Expand culture, 200r/min, 37 DEG C, 12h in fluid nutrient medium.The big extraction reagent kit of endotoxin is gone largely to extract matter using plasmid
Grain surveys plasmid concentration, digestion and sequence verification.As needed, plasmid normal saline dilution is to various concentration, -20 after packing
It DEG C stores for future use.
2nd, experimental animal immunity test:
100 3 week old Kunming mouses of female are randomly divided into 10 groups, and (original body mass for ensureing each experimental group of weighing is without significance difference
It is different), 10/group, indoor temperature is always held at 28 degree or so.Animal house is always maintained at cleaning, health in phase experimental period, in time
Fecaluria in house is removed, keeps dry in house.With " 3.1 softwares of orthogonal design assistant II " design 3 factors (vaccine, immunizing dose,
Immune time), 3 level (pEGFP-N1, pEGS/2SS, pEGS/2SS-tpa;It is basic, normal, high;2 times, 3 times, 4 times) orthogonal examination
It tests.Experiment is grouped as follows:
2 mouse immuning test of table is grouped
Mouse is immunized according to grouping, takes mouse quadriceps muscle of thigh multi-point injection, being spaced 2w after first immunisation strengthens
It is immune, the mind & body situation of continuous one week observation mouse after being immunized.Mouse routinely feeding standard, changes weekly bedding and padding 2 times,
It is freely eaten and drinks water.
3. mouse is weighed
It weighs before first immunisation to mouse, just exempts from rear 2w, 4w, 6w, 8w and weigh to mouse, and record weight number
According to until off-test.
Before just exempting from, just exempt from rear 2w, 4w, 6w, 8w and weigh to test mice, record changes of weight rule, find mouse
Growth from 3 week old to 5 week old (i.e. after initial immunity in 2 weeks) is most fast, and weightening later gradually slows down, this and Kunming mouse growth are sent out
The weightening rule for educating the phase is consistent (scape will loyalty etc. 1996).To vaccine, dosage and add respectively and exempt from number and do one-way analysis of variance, show
Show that different vaccine immunities have an impact female rat weightening, and different dosage groups and weight differences that are different plus exempting from time array are unknown
It is aobvious.It is wherein as shown in table 3 to the one-way analysis of variance of different vaccines, it can be clearly seen that pEGS/2SS immune groups, pEGS/
The first starting weight of 2SS-tpa immune groups and control group mice is basically identical, just exempts from rear 4w (i.e. before second of booster immunization) pEGS/
There were significant differences, but pEGS/2SS-tpa compared with control group for the weightening of the female rat of 2SS immune groups and pEGS/2SS-tpa immune groups
The female rat of immune group increases weight without significant difference compared with pEGS/2SS immune groups, although the weightening of pEGS/2SS-tpa immune groups is omited
Higher than pEGS/2SS immune groups;Just exempt from the rear 4-8 weeks female rat speed of growth to slow down, it is seen that the female rat of pEGS/2SS-tpa immune groups increases
Though tuple value is numerically still slightly above pEGS/2SS immune groups and control group without the significance difference opposite sex;
By just exempt from Shi Qizhi it is finally immune after 2w stop, the female rat growth period total augment weights of different vaccine groups difference, i.e.,
The weightening of the female rat of pEGS/2SS-tpa immune groups and pEGS/2SS immune groups is all remarkably higher than control group, but pEGS/2SS-tpa exempts from
Difference is not notable between epidemic disease group and pEGS/2SS immune groups.The growth traits of mouse is weighed with the body weight gains of mouse growth phase, is said
Bright vaccine pEGS/2SS-tpa and pEGS/2SS can improve the growth rate of female mice, and vaccine pEGS/2SS-tpa is to female mice
Growth-promoting effect is slightly better than vaccine pEGS/2SS.
The influence that the different vaccine immunities of table 3 increase weight to female rat
Note:The postposition letter of any two number is identical in same row is considered as the not notable P of difference>0.05, it is on the contrary then be considered as
The not notable P of difference<0.05.
4. the immune influence to MOUSE REPRODUCTION character
4.1 mouse litter sizes and newborn mouse weightening
When 11 week old of mouse (i.e.) launches a public mouse per cage after the immune 2w of last time, mates, next day observation female rat the moon
Road bolt is checked whether and is successfully bred.Hereafter the pregnancy status of female rat is paid attention in 21d, records female rat pregnancy cycle, litter size in detail
And newborn mouse birth weight and weaning weight (i.e. 3 week old of newborn mouse).
It breeds in 11 week old of female rat, gestational period 20-23d records female rat nest litter size, female between different vaccine processing groups
Mouse litter size difference is not notable (table 4).But we still can be seen that embodies superiority, pEGS/ in the number of mouse
2SS-tpa vaccine experiments group is more 1 higher than pEGS/2SS growth hormone release inhibiting hormone positive controls, and pEGFP-N1 up to 1.4 is organized than feminine gender
≈ 2.Illustrate that pEGS/2SS-tpa vaccines still have certain superiority on the reproductive performance of female rat.
The farrowing situation of the different immunization ways female rats of table 4
Note:The postposition letter of any two number is identical in same row is considered as P>0.05, it is on the contrary then be considered as P<0.05.
Nest increases weight during recording newborn mouse lactation, nursing period 21d, and the lactation of female rat is weighed with nest weightening during newborn mouse lactation
Shape.The nest weightening no significant difference of the newborn mouse nest weightening of different disposal group, pEGFP-N1 injections group and blank control group is made a general survey of,
There were significant differences for the weightening of newborn mouse nest between remaining processing group group.Then to vaccine, immunizing dose and add respectively and exempt from 3 factors of number and carry out
Single factor analysis:Different vaccines show the one-way analysis of variance (table 4 (a)) of newborn mouse weaning weight, be immunized pEGS/2SS and
Weaning weight dramatically increases after pEGS/2SS-tpa, and the weaning weight after immune pEGS/2SS-tpa is significantly higher than pEGS/2SS and is immunized
Group illustrates that the milk performance of female rat, wherein pEGS/2SS-tpa can be promoted after immune pEGS/2SS and pEGS/2SS-tpa really
Rush lactogenic result it is more preferable;Various dose shows that high dose is immunized to the one-way analysis of variance (table 4 (b)) of newborn mouse weaning weight
Weaning weight be immunized higher than middle dosage but difference is not notable, there were significant differences with low dosage for high dose, middle dosage, illustrates high agent
Amount (200 μ g) is immune can to remarkably promote lactation;Difference, which adds, exempts from one-way analysis of variance (table 4 (c)) of the number to newborn mouse weaning weight
It has been shown that, add exempt from 1 time with plus exempt from 2 times weaning weight difference it is not notable, but be all remarkably higher than plus exempt from 3 times, illustrate the rush for exempting from 1 time is added to secrete
Newborn effect is preferable.In short, different vaccines, immune time and immunizing dose make a significant impact newborn mouse weaning weight, it is contemplated that
Newborn mouse weaning weight is mainly influenced by female rat milking capacity;2 pEGS/2SS-tpa are immunized to female mice using high dose (200 μ g)
The facilitation effect of lactation is best.
Influence of table 4 (a) the difference vaccine immunity to newborn mouse weaning weight
Influence of table 4 (b) immunizing dose to newborn mouse weaning weight
Influence of table 4 (c) immune time to newborn mouse weaning weight
Note:The postposition letter of any two number is identical in same row is considered as the not notable P of difference>0.05, it is on the contrary then be considered as
The not notable P of difference<0.05.
5th, the transcription detection of RT-PCR testing goals gene
5.1 total tissue RNAs are extracted
After immune 5d every group randomly select 1 mouse acquisition heart, liver, spleen, lung, kidney, injection site muscle, small intestine, stomach,
Brain, pancreas extract tissue RNA with Trizol methods, and detailed step is as follows:
(1) liquid nitrogen grinding:Tissue block is directly placed into mortar, adds in a small amount of liquid nitrogen, rapid to grind, and treats that tissue softens, then
Add a small amount of liquid nitrogen, then grind, so three times;
(2) it is homogenized:Tissue sample adds in Trizol by 50-100mg/mL Trizol, is fully homogenized about with electric homogenizer
Need 1-2min;
(3) after tissue adds Trizol, 5min is placed at room temperature for, it is made fully to crack;
(4) 12,000rpm centrifuge 5min, abandon precipitation;
(5) chloroform is added in by 200 μ L chloroforms/mL Trizol, 15min is placed at room temperature for after vibrating mixing;
(6) 4 DEG C of 12,000g centrifuge 15min;
(7) upper strata aqueous phase is drawn, until in another centrifuge tube, isopropanol mixing is added in by 0.5ml isopropanols/mL Trizol,
It is placed at room temperature for 5-10min;
(8) 4 DEG C of 12,000g centrifuge 10min, abandon supernatant, RNA is sunken to tube bottom;
(9) 75% ethyl alcohol is added in by 75% ethyl alcohol of 1mL/mL Trizol, mildly vibrates centrifuge tube, suspend precipitation;
(10) 4 DEG C of 8,000g centrifuge 5min, abandon supernatant as possible;
(11) 5-10min is dried or be dried in vacuo to room temperature;
(12) with 50 μ L DEPC H2O dissolving RNA samples, 55-60 DEG C, 5-10min;
(13) OD values are surveyed and quantifies RNA concentration, between A260/A280 values answer 1.6-1.8, and make agarose gel electrophoresis inspection
Whether degrade.
1 each tissue of mouse acquisition is randomly selected after initial immunity 5d for every group, and tissue RNA is extracted with Trizol methods, RNA's
For agarose gel electrophoresis detection figure as shown in the figure, tri- band of 28S, 18S and 5S is high-visible, the RNA of mesencephalic tissue has drop
Solution trend;Concentration is differed in 300-1000ng/ μ L, OD260/OD280Value illustrates that the tissue of extraction is total between 1.8~2.0
RNA purity is preferable, available for follow-up test.(Fig. 8)
5.2 reverse transcriptions (method is with reference to reverse transcription method step in embodiment 2)
The amplification of 5.3 target gene SS
After the cDNA of reverse transcription is made 5 times of dilutions, the endogenous SS of PCR amplification (design of primers is shown in Table 5).
Growth hormone release inhibiting hormone design of primers in 5 cell of table
PCR amplification system is as follows:
Reaction condition is 95 DEG C of pre-degeneration 3min, 95 DEG C of denaturation 30s, 60 DEG C of annealing, 30,72 DEG C of extension 15s, expands 35
After cycle, 72 DEG C of 5min, 15 DEG C of 2min.Amplified production is detected through agarose gel electrophoresis, and whether verification growth hormone release inhibiting hormone is small
Normal transcription in mouse body.
Each tissue RNA of extraction obtains cDNA, then respectively using each tissue cDNA as template amplification growth hormone release inhibiting hormone through reverse transcription,
It was found that each group of the central nervous system (such as brain) and digestive system (such as stomach, intestines) in addition to endogenous growth chalone normal distribution
Other than knitting, also there is faint band in the tissues such as heart, lung, kidney and injection site muscle.Illustrate in injection growth hormone release inhibiting hormone
After gene vaccine, the growth hormone release inhibiting hormone segment in plasmid can be transcribed in each histoorgan of mouse.(Fig. 9)
6. mouse blood and tissue sampling
6.1 mouse bloods acquire
Before immune and after the test, with docking blood collection method acquisition mouse blood, 20 μ L EDTA have been collected in it and have resisted
In the 1.5mL EP pipes of solidifying agent/pipe, 3,000r/min centrifugation 10min carefully draw upper plasma, and packing about 200 μ L/ pipes are put
It is saved backup in -20 DEG C.
6.2 mouse tissues acquire
Vertebra puts to death mouse, the heart of every group of anatomical acquisition some animals, liver, spleen, lung, kidney, injection part after the test
Position muscle, small intestine, stomach, brain, ovary (ovary is weighed), are placed in 4% paraformaldehyde fixer, each group of another part mouse
It is collected in centrifuge tube after knitting organ acquisition, -80 DEG C of preservations.
7. associated hormone and antibody test
The detection of 7.1 growth hormone, prolactin and growth hormone release inhibiting hormone
The content of hormone GH, PRL and SS in the mice plasma of different disposal are detected with one step Sandwich ELISA of double antibody,
It is as follows:
(1) lath needed for being taken out from the aluminium foil bag after equilibrium at room temperature 20min, remaining lath valve bag sealing put back to 4
℃;
(2) standard sample wells and sample aperture, standard sample wells is set respectively to add the 50 μ L of standard items of various concentration;
(3) sample aperture first adds 10 μ L of sample to be tested, then adds 40 μ L of Sample dilution;Blank well is not added with;
(4) in addition to blank well, the detection that horseradish peroxidase (HRP) marks is added in standard sample wells and sample aperture per hole
100 μ L of antibody seal reacting hole with sealing plate film, and 37 DEG C of insulating boxs incubate 60min;
(5) liquid is discarded, is patted dry on blotting paper, cleaning solution is filled it up with per hole, stands 1min, gets rid of cleaning solution, on blotting paper
It pats dry, so repeats board-washing 5 times;
(6) substrate A, each 50 μ L of B are added in per hole, 37 DEG C are protected from light incubation 15min;
(7) it is added in terminate liquid 50 μ L, 15min per hole, the OD values in each hole is measured at 450nm wavelength;
(8) standard curve is drawn, (calculated value is multiplied by 5 according to the concentration of GH, PRL and SS in standard curve calculating sample
Ultimate density value).
7.1.1 the secretion level of growth hormone
Double-antibody sandwich elisa detection GH calibration curve formula be:Y=-0.30+8.94X-14.86X2+18.49X3-
6.08X4, wherein Y is GH concentration (ng/mL), and X is OD values at 450nm (see annex).The OD that will be measured450It is bent that value substitutes into this standard
In line formula, the GH concentration in mice plasma is calculated.T check analyses are done between any two to different disposal group and control group,
It is variant.Therefore, to vaccine, immunizing dose and add respectively and exempt from 3 factors of number and carry out single factor analysis, find different immunizing agents
Amount and immune time have no significant effect the concentration of GH, but GH content differences are notable in mouse blood after different vaccine immunities,
Compared with unloaded injection group, the secretory volume of mouse GH is promoted after immune pEGS/2SS and pEGS/2SS-tpa, but flesh
Mouse GH is improved not notable after meat injection pEGS/2SS, and mouse GH contents are significantly higher than injection after injecting pEGS/2SS-tpa
Mouse (the P of pEGS/2SS<0.05).Illustrate that somatostatin DNA vaccine pEGS/2SS can increase the release of GH after being immunized, insert
This effect is more obvious after entering tpa signal peptides, although not showed in the growth traits of mouse.(Figure 10)
7.1.2 the secretion level of prolactin
Double-antibody sandwich elisa detection PRL calibration curve formula be:Y=-1.20+22.96X-30.46X2+
70.88X3-32.56X4, wherein Y is PRL concentration (ng/mL), and X is OD values at 450nm (see annex).The OD that will be measured450It is worth generation
Enter in this calibration curve formula, the PRL concentration in the mice plasma obtained does the T check analyses between group two-by-two, shows different groups
Between PRL concentration it is variant.Therefore, to vaccine, immunizing dose and add and exempt from 3 factors of number and carry out single factor analysis respectively, send out
The existing influence of different immunizing doses and immune time to PRL concentration is not notable, but PRL in mouse blood is immunized after different vaccines
The significant difference of content, compared with unloaded immune group, the mouse PRL contents of pEGS/2SS and pEGS/2SS-tpa immune groups are equal
It is improved;And mouse PRL contents significantly raising compared with injecting the mouse of pEGS/2SS after intramuscular injection pEGS/2SS-tpa
(P<0.05), the difference extremely significantly (P compared with control group mice<0.01).Illustrate to increase after being immunized by somatostatin gene
Add the secretion of mouse PRL, and this facilitation is especially apparent after tpa signal peptides are inserted into, this result and female rat lactation
Character result is corresponding, and can fully explain the phenomenon that immune rear female rat milking capacity improves.(Figure 11)
7.1.3 the secretion level of growth hormone release inhibiting hormone
Double-antibody sandwich elisa detection SS calibration curve formula be:Y=-1.31+32.39X-56.62X2+86.87X3-
32.52X4, wherein Y is SS concentration (pg/mL), and X is OD values at 450nm (see annex).OD values at the 450nm of sample are updated to
In above-mentioned standard curve equation, the concentration of SS in mice plasma is calculated.Are done by T two-by-two and is examined for different disposal group and control group and is divided
Analysis, SS contents no significant difference in mouse blood between finding different groups.Further to vaccine, immunizing dose and add exempt from number 3
Factor individually carries out single factor analysis, finds different vaccines, different immunizing doses and different immune times not to the concentration of SS
It makes a significant impact.Influence of the different vaccine immunities to SS contents in mouse blood is immunized as a result, compared with unloaded injection group
The secretory volume of mouse SS is declined after pEGS/2SS, but is declined not notable;Mouse SS content backs after immune pEGS/2SS-tpa
And higher than the mouse of control group, although difference is not also notable.Illustrate somatostatin DNA vaccine pEGS/2SS and pEGS/2SS-
After tpa is immunized, the SS in mouse blood will not be significantly affected.(Figure 12)
The detection of 7.2 somatostatin antibodies
With the generation situation of SS antibody in indirect ELISA method detection immunized mice body, it is as follows:
(1) 96 hole elisa Plates coating standard growth chalone antigen (Sigma-Aldrich, S9129) 100ng/100 μ per hole
L, 4 DEG C of overnight incubations;
(2) reaction solution is abandoned, PBST is washed 5 times, 300 μ L/ holes, each 1min;
(3) add 200 μ L/ holes of confining liquid (i.e. 1%BSA solution), 37 DEG C of incubation 1h;
(4) reaction solution is abandoned, PBST is washed 5 times, 300 μ L/ holes, each 1min;
(5) add test plasma (1:200 dilutions) 100 μ L/ holes, while negative control hole, non-specific adsorption hole are set (i.e.
PBST replaces blood plasma) and zeroing hole, 37 DEG C of incubation 1h;
(6) reaction solution is abandoned, PBST is washed 5 times, 300 μ L/ holes, each 1min;
(7) add sheep anti-mouse igg-HRP (Boster, BA1050,1:2000 dilutions) 100 μ L/ holes, 37 DEG C of reaction 1h;
(8) reaction solution is abandoned, PBST is washed 5 times, 300 μ L/ holes, each 1min;
(9) add 150 μ L/ holes of tmb substrate developing solution, be protected from light 25min;
(10) add 2mol/L H2SO450 μ L/ holes of terminate liquid terminate reaction, and each hole is measured at 450nm wavelength in 15min
OD values.
According to the concentration and OD of SS antibody standard substances450Value draws standard curve, and sample is surveyed OD450It is worth substitution standard
Curve, multiplied by the SS antibody concentrations for 200 being sample.The SS antibody concentrations of test group with the SS antibody concentrations of negative blood sample into
Row standardization correction, to exclude influence of the non-specific adsorption to result.
Calculate the average OD of negative blood sample to be measured450It is worth (XN) and standard deviation (SN), obtain yin and yang attribute critical value XN+2SN。
If the OD of sample to be tested450Value >=XN+2SN, then it is judged to the positive;Conversely, then it is judged to feminine gender.Every group of positive mice number is recorded,
And count the antibody positive rate of different tests grouping.
7.2.1 somatostatin antibody positive rate
According to the OD of positive blood sample450Value >=XN+2SN, judge the mouse number of every group of generation positive antibody, calculate each experiment
The antibody positive rate of group.As shown in Table 6, pEGS/2SS immune groups and pEGS/2SS-tpa immune groups, which have, generates the small of SS antibody
Mouse, and the antibody positive rate of pEGS/2SS-tpa immune groups is higher than pEGS/2SS immune groups;Under different immunizing dose processing, high agent
The antibody positive rate of amount group (200 μ g) is higher than middle low dose group;To difference plus exempt from number and analyze, add and exempt from the antibody sun of 1 time
Property rate is slightly higher.Therefore, for antibody positive rate, using the immune of immune 2 pEGS/2SS-tpa of high dose (200 μ g)
Best results.
The antibody positive rate of table 6 (a) difference vaccine group mouse
The antibody positive rate of table 6 (b) difference immunizing dose group
Table 6 (c) is different plus exempts from the antibody positive rate of time array
Claims (4)
1. a kind of genetic engineering bacterium, it is characterised in that:Escherichia coli Escherichia coli DH5 α (pEGS/2SS-tpa),
Deposit number:CCTCC NO:M2015105.
2. the plasmid pEGS/2SS-tpa that bacterial strain described in claim 1 includes.
3. plasmid described in bacterial strain described in claim 1 or claim 2 is preparing while is promoting mouse growth, breeding and lactation epidemic disease
Application in seedling.
4. method that is a kind of while promoting mouse growth and lactation, including 200 μ of plasmid g/ times described in claim 2 is immune
Mouse 2 times.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510175578.5A CN104789514B (en) | 2015-04-14 | 2015-04-14 | A kind of amicine overexpression DNA vaccination and construction method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510175578.5A CN104789514B (en) | 2015-04-14 | 2015-04-14 | A kind of amicine overexpression DNA vaccination and construction method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104789514A CN104789514A (en) | 2015-07-22 |
CN104789514B true CN104789514B (en) | 2018-06-15 |
Family
ID=53554709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510175578.5A Expired - Fee Related CN104789514B (en) | 2015-04-14 | 2015-04-14 | A kind of amicine overexpression DNA vaccination and construction method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104789514B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107149684B (en) * | 2017-05-08 | 2019-10-25 | 西南大学 | The new application of cysteine dioxygenase, gene and its catalysate cysteine sulfinic acid |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101050448A (en) * | 2006-12-26 | 2007-10-10 | 华中农业大学 | Oral recombined DNA vaccine for accelerating growth of animal, and application |
CN101092631A (en) * | 2007-05-31 | 2007-12-26 | 华中农业大学 | Modified ORF2 gene of toroidal virus of pig, and application |
CN104479025A (en) * | 2014-08-08 | 2015-04-01 | 重庆医科大学 | Construction, expression and purification and functional identification of tissue plasminogen activator |
-
2015
- 2015-04-14 CN CN201510175578.5A patent/CN104789514B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101050448A (en) * | 2006-12-26 | 2007-10-10 | 华中农业大学 | Oral recombined DNA vaccine for accelerating growth of animal, and application |
CN101092631A (en) * | 2007-05-31 | 2007-12-26 | 华中农业大学 | Modified ORF2 gene of toroidal virus of pig, and application |
CN104479025A (en) * | 2014-08-08 | 2015-04-01 | 重庆医科大学 | Construction, expression and purification and functional identification of tissue plasminogen activator |
Non-Patent Citations (3)
Title |
---|
猪乙型脑炎病毒DNA疫苗载体的构建及其免疫原性研究;孟丽军;《中国优秀硕士学位论文全文数据库,农业科技辑》;20110415;正文第35页第3.1节-40页第3.9节,第52页表2,第4.4节 * |
生长抑素DNA疫苗pEGS/2SS的构建及表达;曹少先 等;《中国兽医学报》;20051231;第25卷(第5期);摘要,第499-500页第1节 * |
生长抑素基因疫苗质粒pcS/2SS的构建、表达及免疫;曹少先;《农业生物技术学报》;20051231;第13卷(第4期);摘要,正文第1段 * |
Also Published As
Publication number | Publication date |
---|---|
CN104789514A (en) | 2015-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103648513B (en) | Yeast-Brachyury (Brachyury) immunotherapeutic composition | |
Akers et al. | Local IGF-I axis in peripubertal ruminant mammary development | |
Trott et al. | Historical perspectives of prolactin and growth hormone as mammogens, lactogens and galactagogues—agog for the future! | |
Fujiwara et al. | Spawning induced by cubifrin in the Japanese common sea cucumber Apostichopus japonicus | |
CN105861458A (en) | Thyroid peroxidase expression method | |
CN102286513A (en) | Tibetan sheep myostatin recombinant expression protein | |
Robinson et al. | Biotechnology—the possibilities | |
CN104450763A (en) | Method for expressing and purifying Leptin A protein of epinephelus coioides and application of Leptin A protein | |
CN104789514B (en) | A kind of amicine overexpression DNA vaccination and construction method and application | |
Bai et al. | Effects of immunization against a DNA vaccine encoding somatostatin gene (pGM-CSF/SS) by attenuated Salmonella typhimurium on growth, reproduction and lactation in female mice | |
WO2013184024A1 (en) | Preparation for increasing sperm production in stud livestock and roosters and method for the use thereof | |
CN104673735B (en) | A kind of cortex chalone growth hormone release inhibiting hormone double expression DNA vaccination and preparation method and application | |
Leibovich et al. | Active immunization of ewes against ovine placental lactogen increases birth weight of lambs and milk production with no adverse effect on conception rate | |
CN111018966B (en) | Hemibarbus maculotus insulin-like growth factor 3, protein thereof, antibody thereof and application | |
CN110819581B (en) | AMH-GNIH double-expression DNA vaccine for improving animal fertility and construction method and application thereof | |
CN112048459B (en) | Salmonella choleraesuis, vaccine and application thereof | |
Roberts et al. | Production of a recombinantly derived growth hormone antibody and the characterization of growth hormone levels in yellow perch | |
CN110372794A (en) | The preparation method and application of Shelled Turtle Trionyx Sinensis Steroidogenic factor 1 polyclonal antibody | |
CN101307104B (en) | Recombination escherichia coli with Z9CCK protein, yolk antibody and applications | |
RU2614115C1 (en) | Recombinant somatostatin-containing protein, method for production, injecting drug to increase meat and dairy efficiency of agricultural animals, and method for drug application | |
Leibovich et al. | Large-scale preparation of recombinant ovine prolactin and determination of its in vitro and in vivo activity | |
CN101289653A (en) | Nicotine-processed dendritic cells for preventing and treating tumors | |
Geale et al. | Efficacy of two adjuvant systems to promote humoral immunity to the pre-proghrelin peptide obestatin in pigs: consequences for the growth of piglets to weaning | |
CN107880135A (en) | One breeder luteinizing hormone releasing hormone recombinant antigen castration vaccine and preparation method thereof | |
CN106434684A (en) | Scatophagus argus luteinizing hormone (LH) gene, scatophagus argus LH recombinant protein and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180615 |